Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, Gandhinagar, Gujarat, India.
Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, Gandhinagar, Gujarat, India.
Biochim Biophys Acta Mol Basis Dis. 2023 Oct;1869(7):166771. doi: 10.1016/j.bbadis.2023.166771. Epub 2023 Jun 5.
To date, various agents and molecules have been developed to treat post-stroke neuroinflammation; however, none of them are clinically successful. Post-stroke neuroinflammation is primarily attributed to microglial polarization as the generation of inflammasome complexes shifts microglia to their M1 phenotype and regulates the downstream cascade. Inosine, an adenosine derivative reported to maintain cellular energy homeostasis in stressed conditions. Although the exact mechanism is still unexplored, various studies have reported that it can stimulate axonal sprouting in different neurodegenerative diseases. Hence, our present study aims to decipher the molecular mechanism of inosine mediated neuroprotection by modulating inflammasome signaling towards altered microglial polarization in ischemic stroke. Inosine was administered intraperitoneally to male Sprague Dawley rats at 1 h post-ischemic stroke and was further evaluated for neurodeficit score, motor coordination and long-term neuroprotection. Brains were harvested for infarct size estimation, biochemical assays and molecular studies. Inosine administration at 1 h post ischemic stroke decreased infarct size, neurodeficit score, and improved motor co-ordination. Normalization of biochemical parameters were achieved in the treatment groups. Microglial polarization towards its anti-inflammatory phenotype and modulation of inflammation were evident by relevant gene and protein expression studies. The outcome provides preliminary evidence of inosine mediated alleviation of post-stroke neuroinflammation via modulation of microglial polarization towards its anti-inflammatory form through regulating the inflammasome activation.
迄今为止,已经开发出各种药物和分子来治疗中风后的神经炎症;然而,它们都没有在临床上取得成功。中风后的神经炎症主要归因于小胶质细胞的极化,因为炎性小体复合物的产生使小胶质细胞向 M1 表型转变,并调节下游级联反应。肌苷是一种腺苷衍生物,据报道它可以在应激条件下维持细胞能量稳态。尽管确切的机制仍未被探索,但许多研究报告称,它可以刺激不同神经退行性疾病中的轴突发芽。因此,我们目前的研究旨在通过调节炎性小体信号来破译肌苷介导的神经保护的分子机制,从而改变缺血性中风中小胶质细胞的极化。在缺血性中风后 1 小时,通过腹腔内给予雄性 Sprague Dawley 大鼠肌苷,并进一步评估其神经缺陷评分、运动协调和长期神经保护作用。采集大脑进行梗死面积估计、生化测定和分子研究。缺血性中风后 1 小时给予肌苷可减少梗死面积、神经缺陷评分并改善运动协调。在治疗组中实现了生化参数的正常化。通过相关基因和蛋白表达研究,观察到小胶质细胞向抗炎表型的极化以及炎症的调节。结果初步提供了肌苷通过调节炎性小体的激活,使小胶质细胞向抗炎表型极化,从而减轻中风后神经炎症的证据。